Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

05/09/2012 | 07:16pm US/Eastern

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043;

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
Latest news on ASTRAZENECA PLC
2d ago ASTRAZENECA : Introduces Fit2Me
5d ago ASTRAZENECA : strengthens partnership with the University of Cambridge
5d ago ASTRAZENECA : and University of Cambridge strengthen long-standing partnership
6d ago Banks could miss out on $135 million fees as Abbvie drops Shire deal
6d ago ASTRAZENECA : Launches Fit2Me, a Free Customized Diet and Lifestyle Support Prog..
6d ago UK minister says Tata steel unit sale a commercial matter
6d ago AbbVie board ditches planned $55 billion Shire acquisition
6d ago US takeover of drugs group Shire is put in doubt by tax clampdown
6d ago ASTRAZENECA : *traders: merrill lynch adds astrazeneca to 'europe 1 list'
6d ago ASTRAZENECA : strengthens partnership with the University of Cambridge
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes